Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 626-640

  Koh, Pek Keng ^a   Faivre Finn, Corinne ^a   Blackhall, Fiona H ^a   De Ruysscher, Dirk ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Antiangiogenic agents; Chemoradiotherapy; Combined modality treatment; EGFR inhibitors; Non small cell lung cancer; Phase I trials; Preclinical models; Radiotherapy; Targeted agents

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; BARASERTIB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CILENGITIDE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; GEMCITABINE; IRINOTECAN; JNJ 38877605; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NAVELBINE; NIMOTUZUMAB; NVP BEP 800; PACLITAXEL; PANOBINOSTAT; PEMETREXED; PHA 680632; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SELUMETINIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VE 821; VELIPARIB; VORINOSTAT;

ACNE; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASTHENIA; BLOOD TOXICITY; BRONCHOPNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COUGHING; DEATH; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG TARGETING; DYSPHAGIA; DYSPNEA; ELECTROLYTE DISTURBANCE; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; GENE TRANSLOCATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEMOPTYSIS; HUMAN; HYPERSENSITIVITY; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOXIA; INFECTION; LIVER TOXICITY; LUNG EMBOLISM; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG INFILTRATE; LUNG INSUFFICIENCY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; METASTASIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PNEUMONIA; RADIATION DERMATITIS; RADIATION PNEUMONIA; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; SYNCOPE; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861694666     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.11.003     Document Type: Review

References (77)

1. 2011 [accessed 12.10.11]. http://globocan.iarc.fr/factsheets/cancers/lung.asp.
2. Coleman M.P., Forman D., Bryant H., et al. ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377(9760):127.
3. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83(6):417-423.
4. De Ruysscher D., Botterweck A., Dirx M., et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009, 20(1):98-102.
5. Groen H.J., van der Leest A., Fokkema E., et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 2004 Mar, 15(3):427-432.
6. Auperin A., Le Pechoux C., Rolland E., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2181-2190.
7. Onishi H., Shirato H., Nagata Y., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2(7):S94-S100. 110.1097/JTO.1090b1013e318074de318034.
8. 2011 [accessed 12.10.11]. http://www.rtog.org/News/tabid/72/articleType/ArticleView/articleId/22/RTOG-0617-Locally-Advanced-NSCLC-Results-at-ASTRO.aspx.
9. Fairchild A., Harris K., Barnes E., et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008, 26(24):4001-4011.
10. Lester J.F., Macbeth F.R., Toy E., Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 2006, 4:CD002143.
11. Bentzen S.M., Harari P.M., Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Prac Oncol 2007, 4(3):172-180.
12. Milas L., Fan Z., Andratschke N.H., Ang K.K. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004, 58(3):966-971.
13. Nyati M.K., Morgan M.A., Feng F.Y., Lawrence T.S. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006, 6(11):876-885.
14. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997, 15(10):1191-1197.
15. Das A.K., Chen B.P., Story M.D., et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 2007, 67(11):5267-5274.
16. Das A.K., Sato M., Story M.D., et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006, 66(19):9601-9608.
17. Baumann M., Krause M., Dikomey E., et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007, 83(3):238-248.
18. Mok T.S., Wu Y.-L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
19. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
20. Hughes S., Liong J., Miah A., et al. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 2008, 3(6):648-651.
21. Hallqvist A., Wagenius G., Rylander H., et al. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite-a phase II study from the Swedish Lung Cancer Study Group. Lung Cancer 2010, 71(2):166-172.
22. Kotsakis A.R., Ramalingam S.S., Tarhini A.A., Heron D.E., Smith R., Friedland D. Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.). (abstr 7019).
23. Blumenschein G.R., Paulus R., Curran W.J., Robert F., Fossella F., Werner-Wasik M., et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011 Jun, 29(17):2312-2318.
24. Dingemans A.-M.B., van Baardwijk G., Reymen A., et al. Determination of standard dose cetuximab together with concurrent individualised, isotoxic accelerated radiotherapy and cisplatin-vinorelbine for patients with stage III non-small cell lung cancer (NSCLC): a phase I study (NCT00522886). J Thorac Oncol 2011, 6(6). abstr MO02.02.
25. Govindan R., Bogart J., Stinchcombe T., et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and leukemia group B trial 30407. J Clin Oncol 2011, 29(23):3120-3125.
26. Gatzemeier U., von Pawel J., Vynnychenko I., et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011, 12(1):30-37.
27. O'Byrne K.J., Gatzemeier U., Bondarenko I., et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011, 12(8):795-805.
28. Chen Y.M., Pandya J., Kelly K.J.K., et al. Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.). abstr 7040.
29. Jatoi A., Schild S.E., Foster N., et al. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol 2010, 21(10):2040-2044.
30. Jensen A.D., Munter M.W., Bischoff H.G., et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer 2011, 117(13):2986-2994.
31. Boland W., Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 2010, 4:289-298.
32. Bebb G., Smith C., Rorke S., et al. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011, 67(4):837-845.
33. Choi H.J., Sohn J.H., Lee C.G., et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung cancer 2011 Jan, 71(1):55-59.
34. Zhou L.L., Liu J., Gong R.-M., et al. A phase II trial of nimotuzumab in combination with chemoradiotherapy in locally advanced lung squamous cell carcinoma. J Thorac Oncol 2011, 6(6). absP4.280.
35. Ready N., Janne P.A., Bogart J., et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 2010, 5(9):1382-1390.
36. Kelly K., Chansky K., Gaspar L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26(15):2450-2456.
37. Rothschild S., Bucher S.E., Bernier J., et al. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial. Int J Radiat Oncol Biol Phys 2011, 80(1):126-132.
38. Ball D., Burmeister B., Mitchell P., et al. Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non small cell lung cancer (" CRITICAL" ): P2-162. J Thorac Oncol 2007, 2(8):S633-S634.
39. Center B., Petty W.J., Ayala D., et al. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol 2010 Jan, 5(1):69-74.
40. Stinchcombe T.E., Morris D.E., Lee C.B., et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008, 3(3):250-257.
41. Ohe Y., Nishiwaki Y., Yokoyama A., et al. Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402. J Clin Oncol 2010, 28(Suppl. 15). abstr 7084.
42. Okamoto I., Takahashi T., Okamoto H., et al. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung cancer 2011 May, 72(2):199-204.
43. Wang J, Xia TY, Wang YJ, et al. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 81(3): e59-65. E pub 2011 Feb 23.
44. Komaki R., Blumenschein G., Wistuba I., et al. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. J Clin Oncol 2011, 29(Suppl.). abstr 7020.
45. Ramella S., Trodella L., Alberti A., et al. MultimodAlity treatment with Radio-chemoTherapy and Erlotinib in advanced NSCLC (MARTE trial). J Thorac Oncol 2011, 6(6). abstr MO02.04.
46. Martinez E., Martinez M., Viñolas N., et al. Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: a prospective randomized phase II study. J Clin Oncol 2008, 26(Suppl.):7563.
47. Wan J., Cohen V., Agulnik J., et al. Unexpected high lung toxicity from radiation pneumonitis in a phase I/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non-small-cell lung cancer(NSCLC). Int J Radiat Oncol Biol Phys 2009, 75(Suppl. 1):S110.
48. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
49. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
50. Spigel D.R., Hainsworth J.D., Yardley D.A., et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010, 28(1):43-48.
51. Stinchcombe T., Socinski M., Moore D., et al. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.). abstr 7016.
52. Kao J., Packer S., Vu H.L., et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009, 115(15):3571-3580.
53. Ma S., Xu Y., Sun X., et al. Endostar in combination with radiotherapy and paclitaxel/carboplatin in patients with unresectable non-small cell lung cancer of stage III: preliminary results of a phase II study. J Clin Oncol 2011, 29(Suppl.). abstr 7043.
54. Siemann D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011, 37(1):63-74.
55. Ng Q.S., Mandeville H., Goh V., et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 2011.
56. Lara P.N., Longmate J., Reckamp K., et al. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer 2011, 12(1):33-37.
57. Edelman M.J., Burrows W., Krasna M.J., Bedor M., Smith R., Suntharalingam M. Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. Lung cancer 2010, 68(1):84-88.
58. Schild S., Molina J., Dy G., et al. A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15 Suppl.). abstr 7085.
59. Sarkaria J.N., Schwingler P., Schild S.E., et al. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol 2007, 2(8):751-757.
60. Decker R., Gettinger S., Glazer P., Wilson L. Vorinostat, a histone deacetylase inhibitor, in combination with thoracic radiotherapy in advanced non-small cell lung cancer: a dose escalation study. J Thorac Oncol 2011, 6(6). abstr P4.252.
61. Singhal N., Penniment M., Gowda R., Brown M. First report: a parallel phase I study of LBH589 in combination with external beam radiotherapy or chemoradiation for locally advanced non small cell lung cancer. J Thorac Oncol 2011, 6(6). abstr P4.284.
62. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26(22):3291-3310.
63. Verheij M., Vens C., van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat 2010, 13(1-2):29-43.
64. Chalmers A.J. The potential role and application of PARP inhibitors in cancer treatment. Br. Med. Bull. 2009, 89(1):23-40.
65. Stingl L., Stuhmer T., Chatterjee M., Jensen M.R., Flentje M., Djuzenova C.S. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010, 102(11):1578-1591.
66. De Bacco F., Luraghi P., Medico E., et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl Cancer Inst. 2011 Apr, 103(8):645-661.
67. Tao Y., Zhang P., Frascogna V., et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007, 97(12):1664-1672.
68. Tao Y., Zhang P., Girdler F., et al. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2008, 27(23):3244-3255.
69. Reaper P.M., Caron P., Charlton P., et al. Evaluation of a potent and highly selective inhibitor of ATR kinase: an approach to selectively sensitize cancer cells to genotoxic drugs. 102nd AACR Annual Meeting Orlando 2011, Poster #5362.
70. Mitchell J.B., Choudhuri R., Fabre K., et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010, 16(7):2076-2084.
71. Sun Y., Moretti L., Giacalone NJ., et al. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol 2011, 6(4):699-706.
72. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
73. Shaw A.T., Yeap B.Y., Solomon B.J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12(11):1004-1012.
74. Harrington K.J., Billingham L.J., Brunner T.B., et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer 2011, 105(5):628-639.
75. Mileshkin L., Hicks R.J., Hughes B.G., et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011, 17(10):3304-3315.
76. Zander T., Scheffler M., Nogova L., et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011, 29(13):1701-1708.
77. Choong N.W., Mauer A.M., Haraf D.J., et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008, 3(9):1003-1011.